Form 4 for VIR Vir Biotechnology, Inc.
Accepted 2024-11-18 00:00:00 ET · period of report 2024-11-15 · accession 0001628280-24-048230 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2024-11-18 | 2024-11-15 | VIR | O'Byrne Jason | EVP, CFO | A - Grant | $0.00 | +75.0K | 75.0K | New | $0 |
| D | 2024-11-18 | 2024-11-15 | VIR | O'Byrne Jason | EVP, CFO | A - Grant | $0.00 | +150.0K | 150.0K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-11-15 | A | A | 75,000 | $0.00 | 75,000 | D | — | — | (F1) Acquisition of restricted stock units pursuant to the Issuer's Equity Incentive Plan. |
| 2 | Derivative | Stock Option (Right to Buy) | 2024-11-15 | A | A | 150,000 | $0.00 | 150,000 | D | $8.64 · — to 2034-11-14 | 150,000 Common Stock | (F2) 25% of the shares subject to the stock option vest and become exercisable on November 15, 2025, and the remaining shares vest in 36 equal monthly installments thereafter. |